您当前的位置：首页 >> 正文

乌苯美司联合伊立替康二线治疗晚期胃癌的临床研究 [中文引用][英文引用]

Clinical study of second-line treatment of advanced gastric cancer with ubenimex combined with irinotecan

[HTML下载] [PDF下载] [发表评论] [查看评论] [加入收藏] [ 397 人次已阅读该文]

作者：盛静1 梅勇2 夏佩3 王晓林4

作者(英文)：

单位：武汉华中科技大学同济医学院附属梨园医院消毒室1 普通外科2 肿瘤科3 消化科4

单位(英文)：

关键词：胃癌化学治疗伊立替康乌苯美司临床疗效不良反应

关键词(英文)：Gastric cancer Chemotherapy Irinotecan Ubenimex Clinical efficacy Adverse effects

分类号：

出版年·卷·期（页码）：2023·1·第5期（317-321）

DOI: 10.3877/cma.j.issn.2095-2015.2023.05.009

-----摘要：-------------------------------------------------------------------------------------------

【摘要】目的：分析对比伊立替康化疗方案与伊立替康联合乌苯美司治疗方案二线治疗晚期胃癌的临床疗效与安全性。方法：回顾性分析2018年1月至2022年1月华中科技大学同济医学院附属梨园医院收治的104例晚期胃癌患者的临床资料，根据患者采取的治疗方案不同，将所有患者分为对照组61例（伊立替康化疗方案）和观察组43例（伊立替康联合乌苯美司治疗方案），两组均以21天为1个周期，共治疗2个周期。比较两组患者在治疗后1周的短期临床疗效、治疗前后外周血中的CD3+、CD4+、CD4+/CD8+水平、治疗后的生活质量、治疗结束1年内的生存情况、治疗期间的不良反应发生率。结果：治疗结束1周后，观察组患者的部分缓解（PR）、客观缓解率（ORR）和总疾病控制率（DCR）显著高于对照组患者（P＜0.05），稳定（SD）和病情进展（PD）显著低于对照组患者（P＜0.05）。治疗前，两组患者外周血中的CD3+、CD4+、CD4+/CD8+水平差异无统计学意义（P＞0.05）；治疗后，两组患者外周血中的CD3+、CD4+、CD4+/CD8+水平均有所上升，且观察组高于对照组（P＜0.001）。治疗后，观察组患者在吞咽困难和进食受限症状领域的评分均显著低于对照组（P<0.05）。1年随访期间，观察组的疾病无进展生存期显著长于对照组[（7.42±0.89）个月 vs （5.35±0.68）个月，P＜0.001]。两组患者在治疗期间的不良反应总发生率，差异无统计学意义（P＞0.05）。结论：伊立替康联合乌苯美司方案治疗晚期胃癌的临床疗效更显著，可以提高患者的机体免疫功能，改善患者的生活质量，延长患者的无进展生存时间，安全性较高。

-----英文摘要：---------------------------------------------------------------------------------------

[Abstract] Objective To analyze and compare the clinical efficacy and safety of irinotecan chemotherapy regimen and irinotecan combined with ubenimex chemotherapy regimen for the treatment of advanced gastric cancer. Methods The clinical data of 104 patients with advanced gastric cancer admitted to Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology from January 2018 to January 2022 were retrospectively analyzed. According to the different treatment plans adopted by the patients, all the patients were divided into control group (irinotecan chemotherapy plan, n=61) and observation group (irinotecan combined with ubenimex treatment plan, n=43), and were treated with 21 days as 1 cycle for a total of 2 Cycle. The short-term clinical efficacy of the two groups at 1 week after treatment, the levels of CD3+, CD4+, CD4+/CD8+ in the peripheral blood before and after treatment, the quality of life after treatment, the survival within 1 year after the end of treatment, and the incidence of adverse reactions during treatment were compared. Results One week after the end of treatment, the partial response (PR), objective response rate (ORR) and disease control rate (DCR) of patients in the observation group were significantly higher than those of patients in the control group (P＜0.05), and the stable disease (SD) and progressive disease (PD) were significantly lower than those of patients in the control group (P＜0.05). Before treatment, there were no statistically significant differences in the levels of CD3+, CD4+ and CD4+/CD8+ in the peripheral blood of the two groups (P＞0.05), but after treatment, the levels of CD3+, CD4+ and CD4+/CD8+ in the peripheral blood of the two groups increased, and the observation group was higher than the control group (P＜0.001). After treatment, patients in the observation group had significantly lower scores in the symptom domains of dysphagia and feeding restriction than those in the control group (P<0.05). During the 1-year follow-up, disease progression-free survival was significantly longer in the observation group than in the control group [(7.42±0.89) months vs. (5.35±0.68) months, P<0.001). Comparing the total incidence of adverse reactions during the treatment period between the two groups, there was no statistically significant difference (P>0.05). Conclusion The clinical efficacy of irinotecan combined with ubenimex in the treatment of advanced gastric cancer is more significant, which can improve the immunity function of the patients, improve the quality of life of the patients, prolong the progression-free survival time of the patients, with higher safety.

-----参考文献：---------------------------------------------------------------------------------------

[01]

欢迎阅读《中华消化病与影像杂志(电子版)》！您是该文第 398 位读者！

若需在您的论文中引用此文，请按以下格式著录参考文献：

中文著录格式: 盛静1,梅勇2,夏佩3,王晓林4.乌苯美司联合伊立替康二线治疗晚期胃癌的临床研究.中华消化病与影像杂志(电子版).2023;1(5):317-321.

英文著录格式: .Clinical study of second-line treatment of advanced gastric cancer with ubenimex combined with irinotecan.No Title Settings.2023;1(5):317-321.